ALS Untangled says clenbuterol needs more study before it can be recommended for ALS
Original source
Clenbuterol (opens in a new tab)ALS Untangled reviewed evidence on clenbuterol, including mouse studies and two small clinical trials in people with ALS. The available findings were described as somewhat promising but difficult to interpret because the trials lacked randomization, blinding and placebo controls. The review says clenbuterol cannot currently be endorsed as a safe or effective ALS treatment.
Why this matters
This does not establish a treatment benefit for people living with ALS. Higher doses may cause serious heart-related side effects, and clenbuterol is not approved by the U.S. Food and Drug Administration for human use in the United States. Further research would be needed before its safety and effectiveness could be judged.
Limitations and context
This is an independent expert review, not a new clinical trial. The cited clinical evidence involved two small, flawed trials without randomization, blinding or placebo controls. The review also notes that lower doses were better tolerated than higher doses, but this does not establish an effective or safe dose.